Novo Nordisk news in 2026: 28 dated events
The latest Novo Nordisk event on this page is dated Sep 29, 2026. elespanol.com reported: Novo Nordisk agrees to buy Chinese weight-loss pill for 2.5 billion euros.
PublicBusiness Consulting and Services10,000+ employeesnovonordisk.comLinkedIn
- Dated events
- 28
- Last 90 days
- 28
- Latest
- Sep 29, 2026
News · latest 10
Latest Novo Nordisk news
Showing 10 of 28 dated events. The Signal API returns all of them.
Get them with one API call- Novo Nordisk agrees to buy Chinese weight-loss pill for 2.5 billion eurosWith Jiangsu Hengrui Pharmaceuticals
- Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596Novo Nordisk has entered into an exclusive license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist, in a deal potentially worth up to $2.6 billion.
- Novo Nordisk A/S - share repurchase programmeNovo Nordisk reported further purchases of its own B shares as part of its ongoing buyback program.
- Novo Nordisk Stock: License Deal with Nanexa SealedNovo Nordisk has entered into a worldwide license agreement with Swedish specialist Nanexa to gain access to its proprietary PharmaShell technology for delayed drug release, a deal potentially worth up to 1.165 billion euros.
- Novo and UNICEF expand partnership to support a healthier start for more than 80 million childrenNovo Nordisk is committing USD 18 million from 2026 to 2030 to a partnership with UNICEF to advance evidence-based policies and prevention services for childhood obesity in seven priority countries.
- Novo Nordisk Stock: CagriSema beats Eli Lilly drug$18M · With UNICEF · 2 stories
- Novo acquires three early-stage obesity programs from Columbia-linked KallyopeNovo Nordisk has agreed to acquire three early-stage obesity drug programs from New York-based Kallyope, Inc.
- Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)Novo Nordisk's once-weekly growth hormone treatment, Sogroya® (somapacitan), received a positive opinion from the European Medicines Agency's CHMP, recommending it for children with idiopathic short stature.
Showing 10 of 28 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Novo Nordisk with the Signal API
One POST /v1/companies/enrich call with novonordisk.com returns Novo Nordisk news signals (news), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"novonordisk.com","signal_types":["news"],"limit":20}'Same industry
News at related companies
Questions about Novo Nordisk news
What is the latest news on Novo Nordisk?
What is going on with Novo Nordisk?
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .